Mylan CEO testified before a House panel that EpiPen prices went up because of investing upgrades, according to NBC. » Read More
A common way of using smartphones fooled two women into thinking they were going blind.
Biotech stocks rallied after a government report said that Medicare cost-cutting measures will not be triggered this year.
Shares of Actuant plummeted more than 7 percent after the company released its fiscal third-quarter earnings.
U.S. House of Representatives Speaker Paul Ryan unveiled a Republican agenda that would repeal Obamacare but keep some of its more popular provisions.
Puberty may be arriving earlier thanks to chemicals, obesity, and other factors, but some say the talk is overblown.
The targets include those who paid the Obamacare penalty or who claimed an exemption to having health coverage.
Opko Health rose more than 5 percent after the U.S. Food and Drug Administration approved the drug Rayaldee.
Big employers will see health costs grow in line with trends, but there's a shift in what's driving spending, PwC's Health Research Institute says.
Emergent BioSolutions moved closer to FDA approval for a large-scale facility for making BioThrax, a vaccine for protection against anthrax.
The jury remains out on whether the slowdown in health spending is due to Obamacare or the overall economy.
The zika virus could already have a foothold in the southern United States, and public health officials are unprepared for it.
Google wants to make it easier for users to find answers to their symptom-related questions with medical information from doctors.
The rapid increase in Zika virus infections in Puerto Rico could put thousands of pregnant women at risk for potential infection.
Shares of Envision Healthcare Holdings dropped more than 5 percent following news of its merger with AmSurg.
Given high health costs in retirement, some workers are better off saving via workplace health savings accounts rather than 401(k) plans.
Big investors are betting that business will boom for this health insurance start-up if Obamacare becomes profitable. And that's a big if.
Get the best of CNBC in your inbox